- Home
- ACXP vs POAI Comparison
ACXP vs POAI Comparison
Compare ACXP & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- POAI
- Stock Information
- Founded
- ACXP 2017
- POAI 2002
- Country
- ACXP United States
- POAI United States
- Employees
- ACXP N/A
- POAI N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- ACXP Health Care
- POAI Health Care
- Exchange
- ACXP Nasdaq
- POAI Nasdaq
- Market Cap
- ACXP 8.4M
- POAI 8.9M
- IPO Year
- ACXP 2021
- POAI N/A
- Fundamental
- Price
- ACXP $0.43
- POAI $0.89
- Analyst Decision
- ACXP Strong Buy
- POAI Hold
- Analyst Count
- ACXP 2
- POAI 1
- Target Price
- ACXP $10.00
- POAI N/A
- AVG Volume (30 Days)
- ACXP 18.4M
- POAI 93.9K
- Earning Date
- ACXP 08-08-2025
- POAI 08-12-2025
- Dividend Yield
- ACXP N/A
- POAI N/A
- EPS Growth
- ACXP N/A
- POAI N/A
- EPS
- ACXP N/A
- POAI N/A
- Revenue
- ACXP N/A
- POAI $1,729,269.00
- Revenue This Year
- ACXP N/A
- POAI $486.27
- Revenue Next Year
- ACXP N/A
- POAI $65.50
- P/E Ratio
- ACXP N/A
- POAI N/A
- Revenue Growth
- ACXP N/A
- POAI 24.17
- 52 Week Low
- ACXP $0.30
- POAI $0.55
- 52 Week High
- ACXP $3.33
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- ACXP 47.99
- POAI 38.00
- Support Level
- ACXP $0.52
- POAI $0.85
- Resistance Level
- ACXP $0.63
- POAI $0.91
- Average True Range (ATR)
- ACXP 0.09
- POAI 0.06
- MACD
- ACXP 0.00
- POAI -0.00
- Stochastic Oscillator
- ACXP 17.33
- POAI 4.12
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.